The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2022 | Feasibility of double autologous stem cell transplantation in patients with AL amyloidosis
Eli Muchtar, MD, Mayo Clinic, Rochester, MN, comments on the results of a study evaluating the feasibility of double autologous stem cell transplantation (autoSCT) in patients with AL amyloidosis. Dr Muchtar explains that due to extensive organ dysfunction, very few patients are eligible to undergo a second transplant. Overall, the study showed that whilst double autoSCT was feasible in these patients, it is important to select patients who have had an adequate response to their first transplant and who have good organ function. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
